• Company/University: Excellerate Bioscience and University of Nottingham, UK
• Interviewee: Dr Nick Holliday (Chief Scientific Officer)
• Products used: PHERAstar FSX, CLARIOstar Plus 
• Method: fluorescence intensity, luminescence, TR-FRET, BRET, drug discovery, protein-protein interaction, binding kinetics

Nick Holliday, Chief Scientific Officer at Excellerate Bioscience and Associate Professor at the University of Nottingham, discusses the company’s role in pre-clinical drug discovery. Excellerate Bioscience, a contract research organization, specializes in developing high-quality assays for various drug types, including small molecules and biologics. They focus on understanding protein-ligand and protein-protein interactions using advanced fluorescence and luminescence technologies. Their preferred methodologies, such as TR-FRET, leverage PHERAstar FSX plate readers to deliver precise kinetic data, enhancing compound profiling and pharmacology. The PHERAstar FSX’s TRF laser excitation and high read frequency are crucial for obtaining high-quality kinetic parameters.